Healthcare -
Biotechnology - NASDAQ - US
$ 9.13
-4.76 %
$ 463 M
Market Cap
-6.62
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tyra Biosciences, Inc.
| Net Income | -86.5 M |
| Depreciation & Amortization | 519 K |
| Capital Expenditures | -664 K |
| Stock-Based Compensation | 22.8 M |
| Change in Working Capital | -729 K |
| Others | -5.87 M |
| Free Cash Flow | -70.4 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (86.5) | (69.1) | (55.3) | (26.3) | (9.3) | (4.1) |
| Depreciation & Amortization | 0.5 | 0.4 | 0.3 | 0.1 | 47 K | 8 K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 2 K | 0 |
| Stock Based Compensation | 22.8 | 13.5 | 10.6 | 2.9 | 0.4 | 0 |
| Other Operating Activities | (5.9) | (1.2) | 3 K | 3 K | 15 K | 0.9 |
| Change in Working Capital | (0.7) | 6.4 | (5.8) | (0.5) | 1.1 | 0.5 |
| Cash From Operations | (69.8) | (50.1) | (50.3) | (23.7) | (7.8) | (2.6) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.7) | (0.8) | (0.6) | (0.7) | (0.3) | 20 K |
| Other Items | (97.7) | (143.8) | 0 | 16 K | 0 | 0 |
| Cash From Investing Activities | (98.4) | (144.6) | (0.6) | (0.6) | (0.3) | 20 K |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 9 K | 17 K | 8 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.6 | 1.5 | 0.6 | 130.1 | 23.5 | 0.2 |
| Cash From Financing Activities | 202.1 | 1.5 | 632 | 311.3 | 23.4 | 0.2 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 34.0 | (193.2) | (50.2) | 287.0 | 15.4 | (2.5) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (70.4) | (50.9) | (50.8) | (24.4) | (8.1) | (2.6) |